BibbInstruments

BibbInstruments Revenue per Share

The Revenue per Share of BibbInstruments (BIBB.SL) as of Oct 19, 2026 is 0.01 SEK.

Revenue per Share

0.01SEK

Last updated:

Revenue per Share of BibbInstruments is 2025 0.01 SEK. Revenue per Share of BibbInstruments was 2024 0.00 SEK. It decreases by % higher compared to the previous year.

The BibbInstruments Revenue per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
Date
Revenue per Share
Jan 1, 2020
0.01 SEK
Jan 1, 2021
0.00 SEK
Jan 1, 2022
0.00 SEK
Jan 1, 2023
0.00 SEK
Jan 1, 2024
0.00 SEK
Jan 1, 2025
0.01 SEK
Jan 1, 2026 (e)
0.03 SEK
Jan 1, 2027 (e)
0.11 SEK
The BibbInstruments Revenue per Share history
YEARRevenue per ShareYoY
est0.11SEK+283.33%
est0.03SEK+199.25%
0.01SEK—
0.00SEK—
0.00SEK—
0.00SEK-100.00%
0.00SEK-96.77%
0.01SEK-55.82%
0.03SEK+10.71%
0.02SEK+250.00%
0.01SEK+3,100.00%
0.00SEK—
0.00SEK-100.00%
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BibbInstruments AB is a specialized medical technology enterprise headquartered in Lund, Sweden, operating within the health care sector. The company focuses on the development and marketing of advanced diagnostic instruments designed for the early detection of cancerous tumors. BibbInstruments went public on the Stockholm Stock Exchange on October 27, 2017, under the ticker symbol BIBB.SL, with the associated ISIN SE0010102095. Despite its technological focus, the organization maintains a lean operational structure, currently employing only four full-time staff members. The core of the company’s innovation lies in its proprietary technology platform known as EndoDrill. This platform utilizes a unique drill function that facilitates early cancer diagnosis, particularly within deep skin tissues and internal organs, offering a minimally invasive alternative to traditional biopsy methods. The product portfolio is diverse and tailored to specific medical needs across various bodily systems. It includes the EndoDrill GI Upper, which is engineered for stomach biopsies, and the EndoDrill GI Lower, designed for intestinal procedures. For respiratory diagnostics, the company offers the EndoDrill GI Lung for lung biopsies. Beyond diagnosis, the portfolio extends into therapeutic applications through the EndoDrill Therapy device, which allows for the passage of displacements in different organs to facilitate the placement of conductors, balloons, and stents for treatment purposes. Additionally, the EndoDrill Needle is available for breast biopsies, while the EndoDrill Model X serves multiple areas and is currently part of an independent research project. The company’s distribution strategy is primarily concentrated on Scandinavian countries, targeting hospitals equipped with endoscopy specialist centers and surgical wards. By focusing on these specific clinical environments, BibbInstruments aims to provide healthcare professionals with precise tools that enhance diagnostic accuracy and patient outcomes. The company’s website, https://www.bibbinstruments.com/, serves as the primary digital hub for information regarding its products and technological advancements. As a small but focused entity, BibbInstruments AB represents a niche player in the global medical device market, emphasizing innovation in early cancer detection through its specialized EndoDrill technology. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Revenue per Share of BibbInstruments is 0.01 SEK in 2025.

On Eulerpool you can find the complete historical development of Revenue per Share BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

Revenue per Share divides total revenue by shares outstanding, showing how much revenue each share represents.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BibbInstruments

All Key Metrics — BibbInstruments